Introduction
Viral replication of Human Immunodeficiency Virus 1 (HIV-1) 1 depends mainly upon three viral enzymes: reverse transcriptase, protease and integrase [1, 2] . as DNA strand transfer (ST) [3, 4] . Once integrated, the provirus persists in the host cell and serves as a template for the transcription of viral genes and replication of the viral genome, enabling the production of new viruses. IN thus represents a novel target for antiretroviral drug design, the more so, as it has no human counterpart. The first two US FDA approved integrase strand transfer inhibitors (INSTIs) were raltegravir (RAL) from Merck and Co [5, 6] and elvitegravir (EVG) from Japan Tobacco Inc. and Gilead Sciences [7] [8] [9] . Both are related to the diketo acid family (DKA), and inhibit the ST reaction by acting at the IN-DNA interface and are highly effective in reducing viral loads. EVG was shown to be a slightly more potent IN inhibitor than RAL [10] [11] [12] [13] . RAL and EVG are administered as part of a multi-therapy treatment of AIDS since 2007 and 2012, respectively. However in the course of treatment, patients undergo viral resistance mutations that can severely limit the efficiency of these drugs [10] [11] [14] [15] [16] . The latest DKA inhibitor, Dolutegravir (DTG) by Glaxo Smith Kline was introduced in the market in 2013. It is endowed with a much lesser sensitivity to emerging HIV-1 resistance mutations than the other INSTIs [17] .
The X-ray structures of RAL, EVG and DTG complexed with the PFV (Prototype Foamy Virus) intasome, a viral PFV DNA-IN-Mg 2+ complex, were solved by Hare et al. [7, 18, 19] . In addition to drug-protein and drug-metal interactions, all three structures showed the onset of extended drug-DNA interactions. These take place: a) between the inhibitor halogenated aromatic ring and the highly conserved 5'C 4 A 3 3'/5'T -3 G -4 3' dinucleotide step; and b) between
the diketo ring and A 3 (shown in red at the 3'end of the oligonucleotides in Figure 1a ), over which it is stacked.
Based on the X-ray structures, we have sought to unravel the contributions of individual viral DNA ends to inhibitor binding. A previous study led by our group [20] using spectroscopy had focused on the determinants of RAL affinity for these ends. Consistent with the X-ray analyses, it showed the RAL-processed viral DNA complex to be predominantly stabilized by the C 4 , A 3 and G -4 bases (shown in red in Figure 1a ). The present study compares EVG and DTG binding to viral DNA, correlating interaction affinities with their reported inhibitory properties [10] . To this aim, we have conducted fluorescence anisotropy experiments complemented by computational studies in the context of the Non Covalent Interaction (NCI) procedure [21] . We have considered the complexes of EVG and DTG with oligonucleotides mimicking processed (LTR32) and unprocessed (LTR34) viral DNA ends. Other oligonucleotide sequences derived from the U5 LTR (Long Terminal Repeats) extremity of viral DNA were also used in the fluorescence anisotropy titrations. All investigated LTR sequences are reported in Figure 1a . The purpose of this study is to put forth whether any increase in drug-DNA affinity correlates with a concomitant decrease of HIV-1 viral resistance mutation [20] .
Materials and Methods

DNA samples and inhibitors
The oligonucleotides LTR34, LTR32, LTR32-I and LTR30 were purchased from 
Fluorescence measurements
The thermodynamic parameters of the drug-DNA complexes were determined using fitting the sigmoidal curves, using the GraphPAD Prism 5 software which applies the non-linear regression (curve fit)-Least square procedure.
PDB entries
The high resolution cryo-EM structure of the HIV-1 intasome (PDB code: 5U1C) was recently resolved [21] . However, the structures of the HIV-1 intasome (IN-HIV-1 viral DNAMg 2+ ) in complex with RAL, EVG and DTG respectively have not been yet determined.
Therefore, in the used computational approach, the complexes were extracted from the X-ray structures of the PFV intasome (IN-PFV viral DNA-Mg 2+ ) in complex with EVG [19] (PDB code: 3L2U) and DTG [20] (PDB code: 3S3M) respectively. PFV intasome crystal structures are generally used due to the lack of HIV intasome crystal structures and on account of structural and functional similarities of the two viruses.
NCI-Plot analyses
The weak interaction zones between the molecules were evaluated using quantum chemistry analyzing the electron density (promolecular) and its reduced gradient through the NCI (Non-Covalent Interaction) procedure with the NCI-Plot Program [22] [23] . This procedure enables a visualization of the intermolecular interactions. The differentiation of the interaction depends on their nature and their strength (the density of the plots). The nature of the interaction can be differentiated by the color of the plot (blue= strong and attractive, green= weak interaction, red= strong and repulsive). This arrangement will also enable G -4 to partake to interactions with the dihalogen ring of DTG/EVG. On another note, the 3'dinucleotide d (T 1 G 2 ) on the unprocessed LTR34, limits the access of the drug to the terminal A 3 adenine. It also reduces the base fraying at A 3 contributing
Results
Fluorescence studies
to an improved stacking with the DKA ring.
NCI-Plot analysis
Closely related recognition motives are highlighted by the crystal structures of the two PFV integrase-DKA inhibitor complexes [18, 19] . On the one hand, the halogenated aromatic rings stack under the processed viral DNA cytosine C 4 , and simultaneously bind to guanine G -4 on the opposite strand. Binding to G -4 is driven by the interaction of the sigma hole prolonging the CF bonds with the electron-rich rings of G -4 . On the other hand, the diketo ring stacks over A 3 .
Analyses of the intermolecular interaction energies of a series of halogenated derivatives with the G -4 -C 4 base pair were recently reported by us by parallel ab initio quantum chemistry and polarizable molecular mechanics calculations [26, 27] . As a complement to these studies, we perform here a topological analysis of the binding of the entirety of both EVG and DTG with an 
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The interaction plots showed in Figure 4 highlight the fact that the intercalation of the drug between the two viral DNA strands is not only guided by the halobenzene ring but also by the rest of the ligand. In fact, intense, large and green plots are recorded in the whole pocket formed by C 4 A 3 -G -4 and either EVG or DTG. These reveal strong non-covalent interactions within the drug-DNA complex. In addition, the green plot represented in Figure 4b for the DTG complex has broader extensions than the one corresponding to the EVG complex (Figure 4a [7, 20, 28, [33] [34] [35] .
There appear to be stringent requirements concerning the sequence of the nucleic bases at the ends of the LTR for retroviral integration [35] [36] [37] [38] [39] [40] , and there is no evidence of mutations in 
